The Cardiology Division, Imizu Municipal Hospital, Toyama, Japan.
Department of Chronic Heart Failure Management, Global Center for Medical Engineering and Informatics, Osaka University, Osaka, Japan.
J Cardiol. 2020 Oct;76(4):325-334. doi: 10.1016/j.jjcc.2020.05.001. Epub 2020 May 28.
Whether beta-blockers improve the clinical outcomes for heart failure with preserved ejection fraction (HFpEF) characterized by variable cardiac pathophysiology remains controversial. This study aimed to clarify cardiac dysfunction affecting the effectiveness of beta-blockers in patients with HFpEF.
Four hundred and nine patients with HFpEF were enrolled retrospectively, and echocardiography and jugular venous pulse were examined to evaluate their cardiac function. The left ventricular (LV) ejection fraction, mean mitral e', mean mitral E/e' ratio, right ventricular (RV) systolic pressure, tricuspid annular plane systolic excursion, and jugular venous pulse waveform were used as indicators of LV contractility, LV relaxation ability, LV filling pressure, RV afterload, RV contractility, and RV diastolic function, respectively. The dominant 'Y' descent of the jugular venous waveform was detected as an established hemodynamic sign of a less-distensible right ventricle.
Two hundred and thirteen patients with HFpEF received beta-blockers. During a mean follow-up period of 33±20 months, 92 patients had cardiovascular events of HFpEF. A less-distensible right ventricle and RV systolic pressure were independent risk factors for cardiovascular events of HFpEF (p=0.016 and p=0.002, respectively). The administration of beta-blockers was not an independent factor, but patients with HFpEF and a distensible right ventricle who received them had fewer events than those who did not (p=0.017). Patients with HFpEF and lower RV systolic pressure (<33mmHg) who received beta-blockers also had fewer events than those who did not (p=0.028). A less-distensible right ventricle or higher RV systolic pressure (≥33mmHg) prevented the beneficial effects of beta-blockers for HFpEF.
Beta-blocker usage was not associated with a reduction in the rate of cardiovascular events of HFpEF, but it may have beneficial effects on HFpEF with preserved RV function. RV function may serve as an indicator to administer beta-blockers to patients with HFpEF.
对于射血分数保留的心力衰竭(HFpEF)患者,β受体阻滞剂是否改善临床结局仍存在争议,其特征是心脏病理生理学变化多样。本研究旨在明确影响 HFpEF 患者β受体阻滞剂疗效的心脏功能障碍。
回顾性纳入 409 例 HFpEF 患者,行超声心动图和颈静脉搏动检查评估心功能。左心室(LV)射血分数、平均二尖瓣 E'、平均二尖瓣 E/e' 比值、右心室(RV)收缩压、三尖瓣环平面收缩位移和颈静脉搏动波形分别作为 LV 收缩功能、LV 舒张功能、LV 充盈压、RV 后负荷、RV 收缩功能和 RV 舒张功能的指标。颈静脉搏动波形的主导“Y”降支被检测为右心室顺应性降低的既定血流动力学征象。
213 例 HFpEF 患者接受了β受体阻滞剂治疗。平均随访 33±20 个月期间,92 例患者发生 HFpEF 心血管事件。顺应性较差的右心室和 RV 收缩压是 HFpEF 心血管事件的独立危险因素(p=0.016 和 p=0.002)。β受体阻滞剂的应用不是独立因素,但接受β受体阻滞剂治疗且右心室顺应性较好的 HFpEF 患者事件发生率低于未接受者(p=0.017)。接受β受体阻滞剂治疗且 RV 收缩压较低(<33mmHg)的 HFpEF 患者事件发生率也低于未接受者(p=0.028)。顺应性较差的右心室或较高的 RV 收缩压(≥33mmHg)会阻碍β受体阻滞剂对 HFpEF 的有益作用。
β受体阻滞剂的应用与 HFpEF 患者心血管事件发生率的降低无关,但对保留 RV 功能的 HFpEF 可能有益。RV 功能可能是 HFpEF 患者应用β受体阻滞剂的指标。